Zetron

Zetron

ondansetron

Manufacturer:

Biolab

Distributor:

Biopharm
Concise Prescribing Info
Contents
Ondansetron
Indications/Uses
Management of nausea & vomiting induced by cytotoxic chemotherapy & RT. Prevention & treatment of post-op nausea & vomiting.
Dosage/Direction for Use
Chemotherapy- & RT-induced nausea & vomiting Adult 8-32 mg daily. Emetogenic chemotherapy & RT: 8 mg by slow IV inj immediately before treatment or orally 1-2 hr before treatment, followed by 8 mg orally every 12 hr for up to 5 days after a course of treatment to protect against delayed emesis. Highly emetogenic chemotherapy: Single dose of 8 mg by slow IV inj immediately before chemotherapy; or 8 mg by slow IV inj immediately before chemotherapy, followed by 2 further IV doses of 8 mg 2-4 hr apart, or by continuous IV infusion of 1 mg/hr for 24 hr; or single dose of 32 mg diluted in 50-100 mL of saline or other compatible fluids & infused over not <15 min immediately before chemotherapy. Continue w/ 8 mg orally bid for up to 5 days after a course of treatment to protect against delayed emesis after 1st 24 hr. Childn 5 mg/m2 IV immediately before chemotherapy, followed by 4 mg orally bid for up to 5 days after a course of treatment. Post-op nausea & vomiting Adult Prevention: 4 mg IM or slow IV inj at induction of anaesth or single dose of 16 mg orally 1 hr prior to anaesth. Treatment: Single dose of 4 mg IM or slow IV inj. Patient w/ hepatic impairment Max total daily dose: 8 mg.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity to ondansetron or other selective 5-HT3 antagonists.
Special Precautions
Not to be used as rescue drug for nausea & vomiting. Use only on scheduled basis; 1st 24-48 hr of receiving chemotherapy. May mask progressive ileus &/or gastric distension. Delayed nausea & vomiting. Moderate or severe hepatic impairment. Pregnancy especially 1st trimester. Not to breastfeed during treatment. Not recommended in childn & elderly in prevention & treatment of post-op nausea & vomiting.
Adverse Reactions
Malaise/fatigue; headache. Drowsiness, fever, dizziness, anxiety, cold sensation; pruritus, rash; constipation, diarrhea; gynecological disorder, urinary retention; increased ALT/AST; inj site reaction; paresthesia, hypoxia.
Drug Interactions
Decreased effect w/ cytochrome P-450 inducers (eg, barbiturates, carbamazepine, rifampin, phenytoin, phenylbutazone). Increased toxicity w/ inhibitors (eg, cimetidine, allopurinol, disulfiram).
MIMS Class
Antiemetics / Supportive Care Therapy
ATC Classification
A04AA01 - ondansetron ; Belongs to the class of serotonin (5HT3) antagonists. Used for the prevention of nausea and vomiting.
Presentation/Packing
Form
Zetron inj 4 mg/2 mL
Packing/Price
5 × 1's
Form
Zetron inj 8 mg/4 mL
Packing/Price
5 × 1's
Form
Zetron tab 8 mg
Packing/Price
10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in